Researchers have identified why some advanced estrogen receptor (ER) positive breast cancers become resistant to hormone therapy, and have identified drugs currently in development that could keep disease stable for longer ...
Feb 7, 2024
0
0
The next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, compared with fulvestrant (Faslodex), in patients with hormone receptor-positive, HER2-negative breast cancer ...
Dec 8, 2022
0
0
In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled the median progression-free ...
Dec 8, 2022
0
6
In a study carried out in mice at the University of Chicago, researchers found that lasofoxifene outperformed fulvestrant, the current gold-standard drug, in reducing or preventing primary tumor growth. It also was more effective ...
May 13, 2021
0
419
(HealthDay)—Treatment with a combination of alpelisib and fulvestrant prolongs progression-free survival among patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative ...
Jun 24, 2019
0
1
(HealthDay)—Piqray (alpelisib) tablets were approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in ...
May 28, 2019
0
1
Women with metastatic hormone receptor-positive breast cancer live longer when they receive a combination of two anti-estrogen drugs, fulvestrant and anastrozole, compared with treatment with anastrozole alone, according ...
Mar 27, 2019
0
0
Combining a targeted drug with hormone therapy substantially extends survival for women with advanced breast cancer, a major clinical trial has found.
Oct 22, 2018
0
8
In 2017 and 2019, the German Institute for Quality and Efficiency in Health Care (IQWiG) had already examined the advantages and disadvantages of ribociclib in combination with an aromatase inhibitor or fulvestrant in comparison ...
Jun 5, 2020
0
3
